AIM Biotech partners with Nikon to provide organ-on-a-chip imaging and analysis contract services for drug discovery
Nikon Corporation announced on Wednesday that AIM Biotech is one of the select organ-on-a-chip (OOAC) providers to support Nikon’s expanding global contract research services for drug discovery. This partnership is a result of collaborative efforts between Nikon and...
How AIM Biotech is automating organ-on-a-chip drug discovery
AIM Biotech is using Opentron’s lab robot to implement automated drug discovery on in vitro platforms that provide more predictive data and higher throughput When the scientists at AIM Biotech developed our idenTx organ-on-a-chip (OOAC) platform for human...
Understanding PD-L1 expression in breast cancer with the idenTx chip
In this last article of the immune checkpoint series, we discuss how scientists used AIM Biotech’s Avatar technology to study when, how, and which cells express the PD-L1 immune protein in breast cancer. PD-L1 expression promotes tumor growth by offering an invasive...
Leveraging AIM’s BioAvatar technology to tackle previously-unknown effects of immune protein ligands in tumors
Although immune checkpoint protein PD-1 activation is known to participate in tumor development and to inhibit adoptive T cell therapy effects, the expression of its ligand PD-L1 during oncogenesis progression is not well understood. A group of scientists studied the...